



TRT
Tissue Regeneration Technologies

Tissue Regeneration Technologies acquires the rights to five new patents to expand its intellectual property portfolio.

June 30, 2011 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA based medical technology company, received the rights to five new patents over the last year in expanding its SoftWave™ technology portfolio.

The five patents cover a variety of medical technologies and represent a significant expansion of TRT's research and development.

Patent name	Patent #	Abstract/Description	Patent Issue Date
Device for Generating Shock Waves	US 7,695,443 B2	A therapy head for medical treatment with shock waves.	04/13/10
Device for the Generation of Shock Waves Utilizing a Thyristor	US 7,775,995 B2	A device for the generation of shock waves for medical therapy.	08/17/10
Pressure Pulse/Shock Wave Therapy Methods and an Apparatus for Conducting the Therapeutic Methods	US 7,841,995 B2	A method for treating various conditions such as arthritis, osteoporosis, gout, and HIV using shockwave technology.	11/30/10
Pressure Pulse/Shock Wave Therapy Methods and an Apparatus for Conducting the Therapeutic Methods	US 7,883,482 B2	A method of reducing or eliminating various masses such as a tumor using shock wave technology.	02/08/11
Pressure Pulse/Shock Wave Therapy Methods and an Apparatus for Conducting the Therapeutic Methods	US 7,905,845 B2	A method of stimulating various tissues, organs, etc. using shock wave technology	03/15/11

TRT was founded in 2005 to develop unfocused SoftWave technology in wound care and

orthopedics and has since expanded its operations to the urology, cardiology, dental and neurological fields. Research has proven that unfocused SoftWave therapy has a strong regenerative effect on all avascular (scar) tissues by stimulating strong biologic responses. The biologic responses include production of growth factors, nitric oxide, and critical gene expressions, which result in angiogenesis and improved blood supply with strong antibacterial properties for treated areas. Conditions that benefit from shock wave treatment include acute and chronic wounds, non-healing bones, ischemic heart tissue, prostatitis and burns.

The company currently sponsors U.S. Food and Drug Administration trials for its “Gold” product line, which is approved in Europe, Asia, Canada and South America. TRT is confident its technologies will dramatically improve patient care and reduce health care costs.

Notice: This press release contains forward-looking statements within the meaning of the federal security laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements. TRT's SoftWave technology is undergoing investigational use in the United States and is not currently available for sale.